XNAS
HTFL
Market cap4.03bUSD
Oct 08, Last price
47.63USD
1D
-3.50%
1Q
78.26%
IPO
58.82%
Name
HeartFlow Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
Key people
William Weldon
Chairman of the Board
Christopher Zarins
Founder · since 2021
Monica Tellado
Chief Financial Officer
Campbell Rogers
Executive Vice President, Chief Medical Officer · since 2017
Kathleen Carey
Senior Vice President - Operations · since 2022
Vikram Verghese
Senior Vice President - Strategy, Business Development and Upsteam Marketing
Charles Taylor
Founder, Chief Scientific Officer, Director · since 2021
Noemi Espinosa
Chief Compliance and Ethics Officer, General Counsel
Joe Riley
Senior Vice President - Sales
Stephen Kam
Senior Vice President - Marketing, Customer Success And International Sales · since 2021
Tim Barabe
Member of the Board of Directors
Julie Cullivan
Member of the Board of Directors
John Farquhar
President, Chief Executive Officer, Director · since 2021
Jeffrey Lightcap
Director
Wayne Riley
Director
Lonnie Smith
Member of the Board of Directors
Director
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | |
| Income | |||
Revenues | |||
Cost of revenue | |||
Unusual Expense (Income) | |||
NOPBT | |||
NOPBT Margin | |||
Operating Taxes | |||
Tax Rate | |||
NOPAT | |||
Net income | |||
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | |||
BB yield | |||
| Debt | |||
Debt current | |||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | |||
| Cash flow | |||
Cash from operating activities | |||
CAPEX | |||
Cash from investing activities | |||
Cash from financing activities | |||
FCF | |||
| Balance | |||
Cash | |||
Long term investments | |||
Excess cash | |||
Stockholders' equity | |||
Invested Capital | |||
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | |||
Price | |||
Market cap | |||
EV | |||
EBITDA | |||
EV/EBITDA | |||
Interest | |||
Interest/NOPBT |